For Business Use Only. Does Not Ship to Residential Addresses. For use inside an Analyzer, Sold Separately.

Thermo Kit Cocaine TSC

https://blockscientific.odoo.com/web/image/product.template/97722/image_1920?unique=0a6a171

Thermo Kit Cocaine TSC

In Stock

1,376.99 1376.99 USD 1,376.99

1,376.99

    This combination does not exist.

     Easily reorder reagents and American-made parts.
     Enjoy the fair price promise.
     Take pressure off your budget (and yourself)

                  

    Product Code: 100086

    Manufacturer: Thermo Scientific

    Shipping Weight: 2.00lbs (0.91kg)

    Specifications

    Control Sets: MGC Multi-Drug Controls

    Description: CEDIA Cocaine Drugs of Abuse Assays

    Detectable Analytes: Benzoylecgonine

    DoA Calibrators: CEDIA Multi-Drug Calibrators

    Quantity: 3 x 17mL

    Storage Requirements: 2° to 8°C

    Intended Use

    The CEDIATM Cocaine assay is an in-vitro diagnostic medical device intended for the qualitative and semiquantitative assay of cocaine metabolites in human urine. 

    Summary and Explanation of the Test

    Cocaine (benzoylmethylecgonine), is derived from the plant species Erythroxylon coca, which is widely grown in South America.

    Cocaine is rapidly metabolized, with less than 5% excreted unchanged in the urine. The two major metabolites, which result from enzymatic and nonenzymatic hydrolysis, are benzoylecgonine and ecgonine methyl ester. The metabolites may be detectable in urine for up to 3 weeks after long term, heavy use of cocaine.

    The CEDIA Cocaine assay uses recombinant DNA technology (US Patent No. 4708929) to produce a unique homogeneous enzyme immunoassay system.11 This assay is based on the bacterial enzyme β-galactosidase, which has been genetically engineered into two inactive fragments. These fragments spontaneously reassociate to form fully active enzyme that, in the assay format, cleaves a substrate, generating a color change that can be measured spectrophotometrically.

    In the assay, drug in the sample competes with drug conjugated to one inactive fragment of β-galactosidase for antibody binding site. If drug is present in the sample, it binds to antibody, leaving the inactive enzyme fragments free to form active enzyme. If drug is not present in the sample, antibody binds to drug conjugated on the inactive fragment, inhibiting the reassociation of inactive β-galactosidase fragments, and no active enzyme will be formed. The amount of active enzyme formed and resultant absorbance change are proportional to the amount of drug present in the sample.